Background and objectives: Creatinine-based estimates of GFR suggest an evolving epidemic of chronic kidney disease (CKD) in U.S. adults that is inadequately explained by conventional, modifiable risk factors. Cystatin C has recently emerged as a promising measure of GFR. To enable further insights into the evolution of CKD in the U.S. population, this study aimed to examine cystatin C levels in U.S. adults.
C hronic kidney disease (CKD) may be important from a public health perspective; it is common, and associated with cardiovascular disease, end-stage kidney disease, death risks in community settings, and substantial health care expenditure (1) (2) (3) (4) (5) . In the last decade, incidence of end-stage kidney disease treated with renal replacement therapy has increased substantially (5, 6) , as has the populationwide burden of treatable CKD risk factors, principally hypertension (7), obesity, and diabetes (8, 9) . However, trends in the burden of CKD are unlikely to be accurately inferred from trends in incidence of end-stage kidney disease. For example, in one notable study comparing 1976 -1980 and 1988 -1994 , CKD prevalence did not keep pace with incidence of end-stage kidney disease treated with renal replacement therapy (10) .
Precise estimates of disease trends are desirable for disease management at a public health level. In this regard, recent observations have generated concern that kidney function in representative U.S. adults may be declining without adequate explanation (11) . These twin observations (increasing disease burden; inability to explain this burden with easily identifiable, modifiable risk factors) may be a cause for concern from a public health perspective.
Cystatin C is a low-molecular-weight protein with attractive properties as a measure of GFR, including near-constant production rates and free filtration by the glomerulus (12) ; in addition, cystatin C levels appear to be independent of sex and race, and the contribution of lean-body mass to cystatin C appears to be less than one-tenth that of true GFR in healthy adults (13) .
Cystatin C levels were measured in a large, systematically sampled group of National Health and Nutrition Examination Survey (NHANES) participants from 1988 -1994 and 1999 -2002 , enabling further insights into the evolution of CKD in the U.S. population.
Materials and Methods

Objectives
The objectives of this study were to compare representative U.S. adult participants in NHANES 1988 NHANES -1994 NHANES and 1999 NHANES -2002 with respect to mean cystatin C levels, the primary objective, and serum creatinine levels, GFR values estimated from serum creatinine (eGFR creatinine ) and cystatin C (eGFR cystatin C ), urinary albumin-creatinine ratios (ACR), and stages of kidney function.
Study Population
NHANES surveys are cross-sectional, multistage, stratified, clustered probability samples of noninstitutionalized U.S. civilian population (14). NHANES III was performed in 2 phases (1988 -1991 and 1991-1994) ; since 1999, NHANES has been performed continuously in 2-yr cycles. For the current study, data from the 1988 -1991 and 1991-1994 cycles were combined to define an earlier study population, and data from 1999 -2000 and 2001-2002 were combined to form a later popula-tion, a strategy recommended by the National Center for Health Statistics (15,16).
NHANES intentionally oversampled certain population subgroups, including the elderly, Mexican Americans, and non-Hispanic African Americans. Participants were interviewed at home, and physical examinations and blood and urine collections were performed in mobile examination centers.
Measurements and Definitions
Selection factors and measurement techniques for cystatin C and serum creatinine are shown in Figure 1 . Cystatin C levels were measured in stored serum samples for all participants aged Ն60 yr; for participants aged 12 to 59 yr, cystatin C levels were measured in a random sample of 25%, in all men with standardized serum creatinine levels Ͼ 1.2 mg/dl, and in all women with levels Ͼ 1.0 mg/dl. For the current study, we limited the population to participants aged Ն20 yr in whom cystatin C levels were measured. Cystatin C levels were measured by a particle-enhanced immunonephelometric assay (N Latex Cystatin C; Dade Behring, Deerfield, IL). This assay has a range of 0.23 to 7.25 mg/L, and interassay coefficients of 5.05% and 4.87% at cystatin C levels of 0.97 and 1.90 mg/L, respectively (17).
Serum creatinine was measured throughout by the kinetic alkaline picrate method. Calibration Verification/Linearity Survey LN24 samples were used to confirm that calibration of the Roche enzymatic method was traceable to methods based on liquid chromatography-isotope dilution gas chromatography mass spectrometry. Ultimately, standardized creatinine values (in mg/dl) were calculated from actual creatinine, as follows: All participants aged ≥ 60 years and random sample of 25% of partiatipants aged 20-59 years, plus all men with standardized serum creatinine levels > 1.2 mg/dL and all women with levels > 1.0. Cystatin C measured by particle-enhanced immunonephelometric assay in 2006 (n = 11,440).
Serum creatinine
Serum creatinine Figure 1 . Selection factors and measurement techniques for cystatin C and serum creatinine.
Park, NC) was used to incorporate the sampling weights implicit in this complex sample survey design (15,23). As recommended by NHANES, we used specific weights that accounted for the probability of having a cystatin C measurement, 
Results
Participants with cystatin C measurements were very similar to their parent populations in both study eras (Table 1 ). In the study population of adult participants with cystatin C measurements, discriminating characteristics (P Ͻ 0.05 versus 1988 -1994) of 1999 -2002 participants were as follows: nonwhite race (28.3% versus 23.4%), presence of diabetes (6.7% versus 5.0%), smoking (20.5% versus 28.7%), and body mass index (28.1 versus 26.6 kg/m 2 ). Mean cystatin C levels (0.9 versus 0.9 mg/L), eGFR cystatin C (94.6 versus 93.1 versus ml/min/1.73 m 2 ), and urinary ACR (5.9 versus 5.8 mg/g) were similar in the two study eras (Table 2 ). In contrast, standardized serum creatinine (0.9 versus 0.8 mg/dl) was higher and eGFR creatinine was lower (87.6 versus 93.2 ml/ min/1.73 m 2 ) in 1999 -2002. Figure 2 illustrates eGFR cystatin C and eGFR creatinine values by study era in subgroups defined by age, sex, and race. The qualitative pattern described above, with similar eGFR cystatin C in both time frames and lower eGFR creatinine in 1999 -2002, was maintained in the subgroups.
As defined by eGFR cystatin C and ACR, distributions of CKD stages were similar in 1988 -1994 and 1999 -2002. As defined by eGFR creatinine and ACR, stage 3a (6.2% versus 4.1%), stage 3b (1.8% versus 1.2%), and eGFR Ͻ30 ml/min/1.73 m 2 (0.5% versus 0.3%) were all more prevalent in the 1999 -2002 population ( Table 2 ). The prevalence of CKD was higher on the basis of cystatin C-based estimates in both earlier (11.1% versus 10. 
Discussion
We found substantial declines in eGFR values on the basis of standardized serum creatinine levels. In contrast, serum cystatin C levels (the primary outcome for this study) and ACRs showed no such trends.
Ideally, to compare a given biologic analyte in different eras, the following might be desirable: measurement in all participants and a single, accurate assay throughout. In this study, while all study participants had serum creatinine measurements, three analyzers were used for the original measurements. Standardization to a single reference standard in 2006 included approximately 1% of NHANES 1988 -1994 participants and was restricted to those aged 60 yr or older (18) . For cystatin C, a systematic sampling design was used; more than 40% of participants were sampled using a single assay. Although issues related to differential sample drift for stored creatinine and cystatin C are theoretically possible, this seems an unlikely explanation for the findings we observed for cystatin C and creatinine-based GFR estimates. It is tempting to speculate that differences in sampling strategies or residual differences in serum creatinine calibration between study eras may be responsible. This being said, it is also possible that findings based on serum creatinine may be correct. In this regard, the findings for eGFR Ͻ 30 ml/min/1.73 m 2 were notable: creatinine-based methods showed 88% and 76% rises in adjusted prevalence ratios, whereas cystatin C-based methods showed no such trend. In addition, differential evolution of nonrenal and renal cystatin C determinants could explain static cystatin C values in the face of a real fall in GFR values.
Some of the population findings based on serum creatinine in this study are similar to those reported by Coresh et al. (11) , who found that prevalence of creatinine-based estimated GFR levels Ͻ 60 ml/min/1. prevalence of GFR values Ͻ 60 ml/min/1.73 m 2 among later participants was inadequately explained by changes in age distribution or by changes in burdens of diabetes, obesity, or hypertension. Other noticeable features of the more recent report were mean serum creatinine values 0.04 mg/dl higher in 1999 -2004 study participants aged 20 to 39 yr without hypertension or diabetes (11) . These findings differed from those of a previous report based on nonstandardized serum creatinine values in NHANES 1988 -1994 and 1999 -2000, which showed stable CKD prevalence estimates (24) .
The limitations of this study deserve attention. Gold standard measurements of kidney function, such as insulin or radioisotope clearance, were not performed. The study was cross-sectional; hence, identification of participants with progressive loss of kidney function was not feasible. When conditions are defined by numerical variables that vary intrinsically within individuals, such as GFR or urinary protein excretion, crosssectional studies can provide reasonable estimates of disease prevalence; all things being equal, it would be expected that individuals showing atypically high values of a given variable would be balanced by individuals with atypically low levels at the time of measurement. In contrast, cross-sectional designs are unsuitable for identifying individual cases, as demonstrating persistently abnormal values requires repeated measurements. In addition, the presence of diabetes and hypertension was based on self-report; possibly, differential ascertainment of these parameters may have occurred in 1988 -1994 and 1999 -2004 .
Despite its limitations, we believe this study provides useful information. The population prevalence of CKD is clearly challenging in scope, and finding an increasing disease burden without apparent explanation could be seen as a major public health concern, as it implies an ongoing epidemic without logical targets for intervention. The disparity between temporal trends when kidney function is addressed with different measurements suggests that estimating trends in disease burden remains an open question.
